BACKGROUND: Obesity is associated with poor quality of life in breast cancer (BC) survivors. In the Look AHEAD trial, participants losing 3-6% of initial weight at 2 months had higher odds of ≥5% weight loss after 1 year, and 45% of participants attained ≥5% weight loss after 2 months. From an ongoing non-randomized clinical trial in BC survivors with excess weight, we examined 2-month weight loss response. METHODS: Women with stage 0-III BC, who completed local therapy and chemotherapy, with a body mass index (BMI) ≥27 kg/m 2 were enrolled on a 6-month BWL consisting of remote coaching, online curriculum and tracking of diet, activity and weight. Participants completed demographic surveys and were weighed in clinic at baseline and 2 months. Weight loss at 2 months stratified patients into those with ≥5% weight loss (FAST-BWL), and those without (SLOW-BWL). We performed a descriptive analysis of demographics and % weight loss from baseline to 2 months. RESULTS: As of 10/20/2021, a total of 25 patients enrolled on trial. One withdrew before starting BWL, and one withdrew before week 9. Of the 23 currently on study, 20 completed the 2-month visit, and 3 are in the first 8 weeks. Among the 20 participants, majority were Caucasian with ECOG 0 (80%) and postmenopausal (90%). The median age at enrollment was 60.5 [range 40, 73] and many were employed (65%). Most had stage I (70%) and II (20%) breast cancer. The median time from diagnosis to study enrollment was 3.5 years [0.64-9.34]. Over half received mastectomy (55%), chemotherapy (50%) and endocrine therapy (65%); only 10% received anti-HER2 therapy. None used tobacco, and median alcohol consumption was 1.25 [0,14] drinks per week. Mean baseline weight was 213 (SD 32) pounds and mean baseline BMI was 35.4 (5.98). Mean HbA1c was 5.5% (0.47), total cholesterol 200 (22), LDL 114 (24), and triglycerides 126 (65). After 2 months of BWL, 9 (45%) attained ≥ 5% weight loss (FAST-BWL), and 11 (55%) did not (SLOW-BWL). These preliminary results are consistent with our preliminary assumptions. CONCLUSIONS: Our results suggest that BC survivors with obesity receiving BWL demonstrate a similar proportion of attaining 5% weight loss early on as the non-cancer population with obesity. As target enrollment is 55 patients, updated data will be reported at conference. Understanding initial weight response will inform populations that may benefit from augmentation with anti-obesity medication.